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THE relationship between host and tumour can be described in two ways, as
an intercellular confrontation between normal and malignant cclls, and as a
relationship between the whole organism and the tumour.
The relationship between normal and malignant cells has been thoroughly
investigated by Abercrombie and Heaysman (1953) who used techniques of tissue
culture to show that explants of fibroblasts which were grown on glass continued
to grow outwards until the cells made contact. It was found that when the
fibroblasts had made contact they stopped growing. Abercrombie and Ambrose
(1958) later found cancer cells were able to make normal cells move out of their
path, and there was no contact inhibition between normal and malignant cells.
These were found to invade normal cells when they were grown together in vitro
as they do in the in vivo situation.
(4oman and Anderson (1955) suggested that the difference in adhesion of
normal and malignant cells may be due to an alteration in the surface ofmalignant
cells. Coman (1961) tested cancer cells and normal cells for both stickiness and
the adhesive properties of two like cells, and found epithelihl cells were strongly
adhesive but only slightly sticky, whereas cancer cells were weakly adhesive but
very sticky. Calcium ions are needed to maintain adhesiveness, and he suggested
that the calcium ions form bonds between cells by linking to carboxyl or phosphate
groups, while cancer cells, which do not bind calcium adequately, are unable to
form such bonds. Also the cancer cell is believed to produce an abnormal quantity
of mucopolysaccharide which combines with calcium ions, thereby preventing or
disrupting linkages between cells.
Weiss (1960) put forward the interesting suggestion that the extramembraneous
layers are adsorbed on to cell surfaces, and that these layers are not only the
precursors of extracellular cement but are also functionally related to collagen
and fibrin. He further demonstrated that sarcoma 37 ascites cells lost 20% of
the dry weight after incubation with trypsin, which loss of weight he believes is
due to liberation of the extraneous coats (Weiss, 1965).
O'Meara and Jackson (1958) have shown that dividing cancer cells are
surrounded by fibrin which. they believe. is essential for tumour growth, and
(laser, Spink and O'Meara (1965) have recently isolated a tumour fraction which
acted as an anticoagulant in high dilutions. The possibility should therefore be
considered that the malignant cell forms a fibrin-like substance from the extra-
cellular membranes. The precise relevance of these findings to the neoplastic
process is not yet clear, but Michaels (1964) reviewed a population of patients
having anticoagulant therapy and found a diminished incidence of malignancy as
compared with the geineral population. Inhibition of tumour growth by localMARY R. ANDERSON AND H. N. GREEN
anticoagulant therapy has also been described by Wood (1958). and againi by
Wood, Holyoke and Yardley (1961).
However, tumour host relationships are best studied at the level of the whole
organism and the tumour, as it is believed that the problem of cancer rests in this
relationship, due to a complicated interplay of substances being emitted by both
tuimour and host.
It is known there is a species variability of responses to chemical carcinogens.
Gruinea-pigs develop delayed type hypersensitivity and respond with contact
dermatitis to the chemical 20-methylcholanthrene which is carcinogenic in other
species. Sulzberger Sherwin and Hermann (1962) have suggested that an animal
may respond by either tumour development or hypersensitivity to topical painting
with a carcinogen. Gordon (1964) tested this theory using six carcinogens and
six non-carcinogenic azo dyes. He found only one non-carcinogenic compound,
2-methyl-4-dimethyl-aminobenzene (the one dye which bound to rat liver protein
without being carcinogenic in rats), gave contact dermatitis in guinea-pigs. All
the substances carcinogenic in rats gave contact dermatitis in guinea-pigs. Eisen.
Orris and Belman (1962) suggested that for a compound to elicit a reaction in a
sensitised animal, it must first combine with host protein. and that this binding
may be dependent on species specific enzyme and nmolecular sizes and be genetically
determined (Humphrey, 1965). Dimethylbenzanthrene is a potent carcinogen
when painted on the skin of rabbits and mice, yet it is almost completely inert
on the guinea-pig (Woodhouse, personal communication). Auto-antibody to
human skin has been described by Parish, Champion arid Rook (1965) in sera
from patients with acute eczema. and in guinea-pigs by Weininger (1954), and
also by Wilhelmj, Kierland and Owen (1962). These authors used an autologous
freeze-pressed skin extract as antigen, which was thought to be a protein complex
precursor of keratin.
Species variability to carcinogens has been studied and an attempt made to
induce an autologous skin antibody in the guinea-pig, and to test the subsequent
effect of skin painting with the carcinogen dimethylbenzanthrene (DMBA)
(Anderson, 1967). In this experiment, it was thought that humoral antibody to
the carcinogen hapten only occurred in the group of animals which had been
sensitised to autologous skin before painting with the carcinogen. If this is so.
the antibody which had been induced to skin components appears to have reacted
with the skin-carcinogen complex during the months ofpainting and. subsequently.
been able to combine with the hapten alone when tested by slide agglutination.
However, this does not appear to be the whole story, as it was possible in the
guinea-pig to induce both carcinogen-protein binding and anti-target-orgall
antibodv without iniducing cancer. Indeed. it is thought that the response of
either tolerance or hypersensitivity which was obtained was associated with the
mechanism which prevents carcinogenesis in this species.
Both auto-immune diseases and. it is thought. malignant diseases are initiated
by antibody attack in man. In the experiment quoted here, there is suggestive
evidence that, in this system. it is possible to elicit an antibody to an organ (skin)
and challenge that organ with a carcinogen, without inducing malignancy. The
associatioin in man between malignancy and hypersensitivity does not appear to
be an alternative phenomenon as that of tolerance or hypersensitivity seems to
be in the guinea-pig. The work of Grace and Dao (1959), Curtis, Blaylock and
Harrell (1952) and of Curtis, Heckman and Wheeler (1961) on dermatomyosis and
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neoplasia demonistrated ani immediate-type hypersensitivity to an autologous
extract of tumour tissues, as well as a passive transfer reaction in a healthyv
volunteer. They suggested that tumour catabolic products were aeting as a
reagin which elicited a hypersensitivity response. However, it is unknown
whether the association is causally related, either the cancer causing the associated
disease or vice versa, or whether both diseases are an expression of some, as vet
occult, process which generates both diseases. It is difficult to see how this point
can be clarified experimentally, but consideration of another chronic disease.
tuberculosis, suggests the possibility of tissue sensitisation.
It has been shown (Anderson, 1964) that a 20-methyl-cholanithrene-induced
fibrosarcoma is capable of inducing an immune response in the spleen of the
autologous tumour-bearing host. Passive cutaneous anaphylaxis constantlv
demonstrated in 31 guinea-pigs a specific immune response between autologous
fibrosarcoma cells and autologous spleen cells. It was also found that when the
spleen cells from an animal bearing a large tumour were used this specific recogni-
tion was not obtained. It was believed that the failure of specific recognition of
tumour cells shown by spleen cells from animals bearing large tumours was due
to a depletion of the immune mechanism. This observation is supported by the
findings of Mikulski, Smith and Alexander (1964), that the growth rate of a,
chemically-induced tumour as transplant in syngeneic host rats is retarded if the
tumour cells are mixed with spleen cells from a syngeneic donor which has been
immunised against the tumour by injections oflethally irradiated tumour material.
Also the protective effect was not obtained if the spleen was obtained from aIn
animal bearing a large tumour. Maximum effect was obtained when the animal
was killed 10-21 days after the tumour had been excised. An effort therefore
was made to elucidate this fragmentary evidence for the presence of an antibody
in neoplastic disease, and results have been obtained which point to an immediate
type hypersensitivity response to preparations made from autologous tumours
in some cases of human neoplastic disease. Anderson and Parsons (unpublished)
found the injection of autologous tumour antigens into the skin of a patient with
widespread cancer appears to cause a flare which is at maximum at about one
hour and is faded by six hours. This flare is larger than that obtained to similar
microsomes which had been heavily irradiated, or to autologous serum. NoIn-
specific traumatic responses of the histamine-kinin type would appear to have
been eliminated as a cause of the flare response by the very marginal response
obtained to autologous serum. (However, care should be taken in accepting
immediate type hypersensitivity responses in too unreserved a fashion. in view
of the findings of Black (1963) who was able to suppress immediate-type hyper-
sensitivity in allergic patients to the specific antigen by direct suggestion under
hypnosis. Hence, there must also be some part of the immune mechaniism under
nervous control).
It is. indeed, theoretically logical that a graft-versus-host reaction initiates a
defective immune response which itself prevents the effective operation of cellular
responses. The position may be even more complicated than this suggests, in
the light of the findings of Bielicky, Jezkova and Malina (1966) who examined
the sera of patients with lupus erythematosis and found the highest titres of
antibody in patients with the mildest forms of the disease. They concluded that
auto-antibody is protective in this disease. and that there is an inverse correlation
between manifestation of the disease and auto-antibody formation.
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The fully neoplastic cell is believed to be eliciting antibody to normal, related
cells, as suggested by Davis, Green and Timms (1961) who demonstrated a cold.
incomplete, non-gamma globulin-type antibody on the red cell of patients with
cancer, which was shown to have a larger than normal plaque size by electron
microscopy studies and later to be of an a-2 type globulin. More recently, anti-
body consumption tests (Anthony and Parsons, 1965) have demonstrated the
presence of a 1 gm or a 1 gG globulin on tumour cells, leucocytes of patients and
animals with spontaneous, induced or transplanted tumours, which agrees with the
work of Brody and Beizer (1963) who found antibody on both tumour cells and
erythrocytes. Hence it appears that the in vivo neoplastic cell may emit either an
antigen and an antibody or an antibody with antigenic specificity (which seems
the more probable), against which the tumour-bearing host responds disastrously.
The concept of a dedifferentiated cell producing antibody, or a malignant cell
derived from tissues which are not normally believed to produce antibody doing
so, is not surprising when the recent findings of Gurdon and Uehlinger (1966) are
considered. He enucleated fertilised frog ova and substituted the nucleus from
an intestinal cell and still obtained normally developed tadpoles. It is evident,
therefore, that differentiated cells still retain potentialities which are not normally
expressed. It is possible that the gammaglobulin which Anthony and Parsons
(1965) found on tumour cells as well as on the leucocytes of patients may be
occluding antigenic terminals on both normal as well as malignant cells, and may
indeed be derived from both host and tumour cells. Hellinan, Duke and Tucker
(1965) studied the effect of thalidomide on homograft rejection in rats and in
mice, and showed that if the host is treated with thalidomide there is a delay in
the rejection of skin homografts. They also found that treating the skin graft
with thalidomide, in a water bath for six hours before grafting, delayed graft
rejection in these species. Whether there is any association between the delay
in rejection of thalidomide-treated skin grafts and the delay in the induction of
chemical carcinogenesis when the lymph nodes draining the area are irradiated
remains to be seen (Anderson, 1963).
Dempster Calnan and Kulatilake (1963) showed that second set rejection of
normal skin homografts could be prevented if the first sensitising graft were
removed within eight days, and Vrubel and Vrubelova (1962) obtained homograft
immunity in rabbits after modifying the lymph nodes draining the area of the
graft. This suggests that a normal homograft emits an antigen-like substance
which passes to the draining lymph nodes where it initiates an immune response.
If malignant tissues bear any resemblance to normal tissues they may also emit
such an antigen-like substance, which would be expected to act as a graft-versus-
host reaction when the host immune response is grossly depleted or paralysed.
Iftissue specific antigen can be deleted from the cell surface by factors extrinsic
or intrinsic to the cell (by an antibody induced against the cell surface or faulty
messenger RNA resultant on a genome alteration caused by irradiation or viral
infection), this deletion should render the cell anonymous. However, the anonv-
mity of the neoplastic cell is different from that of the chimeral cell. which is
unrecognised by its host, and does not react against the host. It is believed that
in the process of losing tissue specific antigens from the cell surface, the neoplastic
cell becomes so altered that it reacts against the host from whom it induces a
defective immune response, which is tumour pro-,mnoting.
It is noteworthy, however, that not only does the skin of cancer patients persist
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longer than skin from healthy controls as a homograft on normal volunteers
(Amos, Hattler and Shingleton, 1965), but normal skin is not rejected by patients
in the terminal stages of cancer at the usual time (Morson, 1962). Hence it
appears possible that not only is the immune system depleted in cancer patients,
but the normal tissues of a cancer patient may be unable to express full antigenic
potentialitv.
It is postulated that there are two or more immune responses taking place in
neoplasia, a host immune response against the tumour and a tumour-versus-host
response. It is believed that it is the latter process, the tumour-versus-host
response, which is responsible for the peculiar malignancy of neoplasia, indeed
some chemotherapeutic agents may exert their beneficial effects by damping down
or blocking the tumour-versus-host reaction. It has been demonstrated experi-
mentally by Megirian (1965) that chlorambucil significantly delays the uptake of
particulate matter from the blood stream by the reticulo-endothelial system. If
chlorambucil blocks uptake of soluble antigens likewise, the possibility is further
increased that this is the mechanism by which the drug exerts beneficial effect
in neoplasia.
Consideration of the preceding observations regarding the interplay between
hlost and tumour makes it appear likely that this relationship is integral to the
understanding of the nature of neoplastic disease.
SUMMARY
It is believed that two immune processes are taking place in established
neoplastic disease, a host versustumourresponse andatumourversushostresponse,
and that these two processes are integral to the disease.
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